Related Experiment Video
Updated: Jun 9, 2026

Ultrasound Based Assessment of Coronary Artery Flow and Coronary Flow Reserve Using the Pressure Overload Model in Mice
Published on: April 13, 2015
Clinical Outcomes of Coronary Computed Tomography Angiography-Derived Fractional Flow Reserve
Kota Komiyama1, Kengo Tanabe1, Eiji Taguchi2
1Division of Cardiology, Mitsui Memorial Hospital.
Insights
Fractional flow reserve computed tomography (FFRCT) is effective for detecting coronary artery disease. This study found no significant difference in 1-year major adverse cardiovascular events (MACE) between FFRCT values ≤ 0.80 and > 0.80.
Area of Science:
- Cardiology
- Medical Imaging
- Health Economics
Background:
- Coronary computed tomography angiography-derived fractional flow reserve (FFRCT) noninvasively detects coronary artery disease.
- FFRCT is covered by health insurance in the UK, USA, and Japan.
- This is the first study to assess 1-year outcomes of FFRCT under health insurance reimbursement.
Purpose of the Study:
- To investigate the 1-year outcomes of FFRCT analysis in patients managed with health insurance reimbursement.
- To evaluate major adverse cardiovascular events (MACE) based on FFRCT values.
Main Methods:
- Prospective enrollment of 410 participants in the multicenter DYNAMIC-FFRCT registry across six Japanese sites.
- Participants underwent FFRCT analysis between October 2019 and November 2021.
- 1-year follow-up for MACE, including all-cause death, myocardial infarction, and acute coronary syndrome hospitalizations.
Main Results:
- Six MACE cases were recorded: four (1.6%) in participants with FFRCT ≤ 0.80 and two (1.3%) in those with FFRCT > 0.80.
- No significant difference in 1-year MACE was observed between the FFRCT ≤ 0.80 and > 0.80 groups.
- Guideline-based therapy (revascularization and/or optimal medical therapy) was administered to all participants post-FFRCT.
Conclusions:
- The study found no significant difference in 1-year MACE between FFRCT ≤ 0.80 and > 0.80 following guideline-based therapy.
- Limitations include the registry's timing post-reimbursement, limited statistical power, and potential selection bias.
- Further research with adequate statistical power is necessary to confirm these findings.
Abstract:
Coronary computed tomography angiography-derived fractional flow reserve (FFRCT) is useful for noninvasively detecting coronary artery disease. This procedure has been covered by health insurance reimbursement in the United Kingdom, the United States of America, and Japan. This is the first study to investigate the 1-year outcomes of the FFRCT, with management covered by health insurance from the DiscoverY of Novel Assessment Myocardial IsChemia by FFRCT (DYNAMIC-FFRCT) registry.In this multicenter DYNAMIC-FFRCT registry, 410 participants who underwent FFRCT analysis under health insurance reimbursement were prospectively enrolled at six Japanese sites between October 2019 and November 2021. In accordance with recent guidelines, all participants received appropriate revascularization and/or optimal medication therapy after FFRCT. The following clinical outcomes through the 1-year defined major adverse cardiovascular event (MACE) were investigated: all-cause death, cardiovascular events including non-fatal myocardial infarction, and unplanned hospitalization for acute coronary syndrome leading to revascularization.Of the six MACE cases, four (1.6%) occurred in participants with an FFRCT value ≤ 0.80, whereas two (1.3%) occurred in a participant with an FFRCT value > 0.80.This analytical study based on the DYNAMIC-FFRCT registry for cardiovascular conditions found no significant difference in 1-year MACE between FFRCT≤ 0.80 and > 0.80 following guideline-based therapy. The registry was started shortly after reimbursement and had limited statistical power and selection bias. Further studies with sufficient statistical power are required.
Related Concept Videos
Imaging Studies for Cardiovascular System V: CT
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT

